Incidence of Refeeding Syndrome in Children With Failure to Thrive

Megan E Coe1, Lucinda Castellano2, Megan Elliott3

  • 1Department of Pediatrics, Children's Hospital of Richmond at Virginia Commonwealth University, Richmond, Virginia; megan.coe@nationwidechildrens.org.

Hospital Pediatrics
|November 10, 2020
PubMed

Insights

Refeeding syndrome was not found in healthy children under 3 years old admitted for failure to thrive (FTT). Routine lab monitoring showed no electrolyte issues, suggesting current practices may be excessive.

Area of Science:

  • Pediatrics
  • Clinical Nutrition
  • Internal Medicine

Background:

  • Failure to thrive (FTT) is a common reason for hospitalization in children under 3 years old.
  • Refeeding syndrome is a potential complication of nutritional rehabilitation in malnourished patients.
  • Current guidelines for monitoring refeeding syndrome in FTT patients are not well-established.

Purpose of the Study:

  • To determine the incidence of refeeding syndrome in otherwise healthy children under 3 years of age admitted for FTT.
  • To evaluate the necessity of routine laboratory monitoring for electrolyte disturbances in this population.

Main Methods:

  • A multicenter retrospective cohort study included 179 patients aged ≤36 months with a primary FTT diagnosis.
  • Exclusion criteria included ICU admission, parenteral nutrition, prematurity, gastrostomy tube feeds, and complex chronic conditions.
  • The primary outcome was laboratory evidence of refeeding syndrome; laboratory work was assessed at admission and post-admission.

Main Results:

  • None of the 179 patients exhibited laboratory evidence of refeeding syndrome.
  • 81% had admission lab work, and 39% had repeat lab work; 6% experienced adverse events from repeat draws.
  • No significant electrolyte derangements indicative of refeeding syndrome were observed.

Conclusions:

  • Routine laboratory monitoring for refeeding syndrome is not indicated in otherwise healthy, hospitalized children under 3 with FTT.
  • Further research is needed to establish evidence-based guidelines for nutritional management and monitoring in this population.
  • Reducing unnecessary laboratory evaluations can improve patient safety and reduce healthcare costs.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
99
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding01:15

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding

Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
523
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
500
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
121
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
120
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
130